XORTX Receives Small and Medium Enterprise Status for the European Union
CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive renal failure, is pleased to announce receipt of Small and Medium Enterprise (“SME“) Statute for theRead More →